Prostate Cancer, Version 1.2014
| Autor: | Eric M. Horwitz, Richard T. Lee, Eric J. Small, James L. Mohler, Andrew J. Armstrong, Sylvia Richey, Stan Rosenfeld, Charles Arthur Enke, Dorothy A. Shead, Michael B. Cohen, Maria Ho, Julio M. Pow-Sang, Robert R. Bahnson, Eric M. Rohren, Michael Kuettel, Celestia S. Higano, Seth A. Strope, Cy A. Stein, James A. Eastham, Sandy Srinivas, Jonathan D. Tward, Thomas A. Farrington, Mark H. Kawachi, Elizabeth R. Plimack, Mack Roach, Philip W. Kantoff, David Miller, Anthony V. D'Amico, Patrick C. Walsh, Gary R. MacVicar, Arnold W. Malcolm |
|---|---|
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 11:1471-1479 |
| ISSN: | 1540-1413 1540-1405 |
| Popis: | The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|